ARTIFICIAL INTELLIGENCE IN BIPOLAR DISORDER MANAGEMENT: ENHANCING DIAGNOSIS, MONITORING, AND PREDICTION

Kelly Yumi Morii[1]
Julia Coradin[2]
Yasmin Vitória Carvalho de Castro[3]
Afrânio Côgo Destefani[4]
Vinícius Côgo Destefani[5]

ABSTRACT: This narrative review delves into the potential of artificial intelligence (AI) in managing bipolar disorder (BD). A comprehensive literature search was conducted across multiple databases, including Scopus, Web of Science, PubMed, IEEE Xplore, ScienceDirect, Directory of Open Access Journals (DOAJ), and JSTOR, focusing on articles published between January 2010 and December 2022. The review identifies promising AI techniques, particularly machine learning (ML) and artificial neural networks (ANN), that enhance diagnostic accuracy and continuously monitor and predict clinical outcomes for BD. AI methods have demonstrated significant potential in differentiating BD from other psychiatric conditions, such as major depressive disorder (MDD) and schizophrenia, with reported accuracies ranging from 49.5% to 96.2%. Moreover, AI-driven systems utilizing smartphones and wearable devices have shown high accuracy in monitoring mood states and predicting mood episode recurrences. Predictive models using ML algorithms have also been effective in forecasting depressive relapses and identifying cognitive dysfunctions in the early stages of BD. The review underscores the transformative potential of AI in BD management, particularly in predicting clinical outcomes, and calls for further research to overcome existing limitations.

2452

INTRODUCTION

Bipolar disorder (BD) is a multifaceted psychiatric condition characterized by cyclical episodes of mania or hypomania and depression, affecting approximately 1-2% of the global population (1). The episodic nature of BD, coupled with its clinical heterogeneity, poses substantial challenges in achieving accurate diagnosis, effective continuous monitoring, and reliable prediction of clinical outcomes. Misdiagnosis is common, often leading to

[1]Centro Universitário São Camilo.
[2]Centro Universitário de Pato Branco- UNIDEP.
[3]Centro Universitário São Lucas (Porto Velho/RO).
[4]Santa Casa de Misericórdia de Vitoria Higher School of Sciences – EMESCAMES, Brazil Molecular Dynamics and Modeling Laboratory (DynMolLab).
[5]Molecular Dynamics and Modeling Laboratory (DynMolLab) Vitória – ES – Brazil.

inappropriate treatment regimens and suboptimal patient management. Furthermore, the variable presentation of symptoms complicates the monitoring process, necessitating innovative approaches to track mood fluctuations and predict relapses (2). In recent years, artificial intelligence (AI) has emerged as a transformative tool with the potential to address these challenges and substantially improve the management of BD. AI encompasses a range of techniques, including machine learning (ML) and artificial neural networks (ANN), which have shown promise in various domains of clinical psychiatry. These technologies can analyze complex datasets, identify patterns, and make predictive assessments beyond human capability, offering a new mental health diagnostics and treatment planning paradigm. This narrative review aims to comprehensively explore the role of AI in enhancing diagnostic accuracy, enabling continuous monitoring, and predicting clinical outcomes in BD. By synthesizing current research findings, we seek to elucidate the potential applications of AI in BD management while also critically examining the challenges and limitations inherent in implementing these technologies in clinical practice. Through this review, we intend to provide a detailed overview of the current state of AI in BD management and highlight areas for future research and development.

2453

METHODOLOGY

A comprehensive literature search used Scopus, Web of Science, PubMed, IEEE Xplore, ScienceDirect, Directory of Open Access Journals (DOAJ), and JSTOR. The search terms included 'artificial intelligence,' 'machine learning,' 'bipolar disorder,' 'diagnosis,' 'monitoring,' and 'prediction,' combined using Boolean operators. The search was limited to articles published in English between January 2010 and December 2022. From the initial 53 articles identified, 14 were selected for full-text review based on their focus on the application of AI in the management of bipolar disorder. The selection process involved screening titles and abstracts to identify studies that met the inclusion criteria of investigating AI-based methods for diagnosing, monitoring, or predicting bipolar disorder. The selected articles were then critically reviewed, and the key findings were synthesized to provide an overview of the current research state and potential AI applications in bipolar disorder management. Possible

limitations of this review include the possibility of missing relevant articles not indexed in the searched databases and the risk of bias in the article selection process.

RESULTS

Enhancing Diagnostic Accuracy

Accurate diagnosis is crucial for the effective management of BD, as misdiagnosis can lead to inappropriate treatment and poor clinical outcomes (3). AI techniques, particularly machine learning (ML) and artificial neural networks (ANN), have demonstrated potential in improving diagnostic accuracy for mood disorders, including BD (4). AI methods, particularly machine learning (ML) and artificial neural networks (ANN), have shown significant potential in differentiating BD from other psychiatric conditions, such as major depressive disorder (MDD) and schizophrenia. With reported accuracies ranging from 49.5% to 96.2%, these methods provide reassurance about the accuracy of diagnosis, instilling confidence in the potential of AI in BD management (4–6).

A systematic review investigated the application of AI in aiding the detection and diagnostic accuracy of mood disorders and predicting suicide risk (4). The review included 21 studies, of which 11 focused on BD. The authors found that ML and ANN algorithms, such as support vector machines (SVM), random forests (RF), and deep learning (DL), showed promising results in differentiating BD from other psychiatric conditions. For instance, a study used an SVM classifier to distinguish BD from MDD and healthy controls based on neuroimaging data, achieving an accuracy of 70.3% (7).

2454

Similarly, a critical review of ML applications in neuroimaging for BD provided methodological suggestions for future research (5). The authors highlighted the potential of ML algorithms in identifying biomarkers and aiding in the differential diagnosis of BD. They emphasized the importance of considering clinical heterogeneity, feature selection, and interpretability of ML models to ensure their clinical utility, providing the audience with a deeper understanding of the complexities in the field.

Another study performed a scoping review of the role of ML in diagnosing BD, including 28 studies (6). The authors found that various ML algorithms, such as SVM, RF, and ANN, were employed to differentiate BD from other psychiatric conditions, with

accuracies ranging from 60% to 96.2%. They also identified challenges such as data heterogeneity, small sample sizes, and the need for external validation, which should be addressed in future research.

Continuous Monitoring

Continuous monitoring of mood states and symptoms is a crucial aspect of effective BD management. It enables the early detection of prodromal symptoms and plays a key role in preventing mood episode recurrences. AI-driven systems have the potential to revolutionize this aspect of BD management by analyzing data from smartphones and wearable devices (8). AI-driven systems have the potential to revolutionize the monitoring of BD by continuously analyzing data from smartphones and wearable devices. This offers a beacon of hope for the future of mental healthcare, making the audience feel optimistic about the potential of AI in BD management. (9,10).

Antosik-Wójcińska et al. conducted a systematic review of smartphone-based monitoring tools for BD, including data analysis, ML algorithms, and predictive modeling (9). The review included 18 studies demonstrating the feasibility and acceptability of smartphone monitoring BD. The authors found that smartphone-based systems can monitor voice data and usage patterns, achieving 67% and 97% accuracy in predicting mood states. For example, a study by Faurholt-Jepsen et al. used smartphone-based voice features and ML algorithms to predict manic and depressive states in BD patients, achieving an accuracy of 72% (11).

2455

Wearable devices, such as sensorized t-shirts, have also shown promise in monitoring mood states in BD patients. Valenza et al. developed the PSYCHE platform, which uses a sensorized t-shirt to track autonomic nervous system signals and assess mood states in BD patients (10). The authors conducted preliminary evaluations of the platform and found that it could accurately recognize mood states with an accuracy of 95.5%. They highlighted the potential of the PSYCHE platform in providing continuous monitoring and early intervention for BD patients.

Predicting Clinical Outcomes

Predicting clinical outcomes and treatment responses is crucial for personalized treatment planning and preventing relapses in BD (12). AI holds significant potential in this domain, as ML algorithms applied to large datasets can predict depressive relapses with reasonable accuracy and identify cognitive dysfunctions in the early stages of BD (13).

Rotenberg et al. explored the use of ML algorithms to predict depressive relapses in BD patients (12). The study included data from 222 BD patients followed up for 12 months. The authors applied various ML algorithms, such as logistic regression, RF, and SVM, to predict depressive relapses based on clinical and demographic variables. The best-performing model (RF) achieved an accuracy of 72.5% in predicting depressive relapses, demonstrating the potential of ML in aiding personalized treatment planning.

Sawalha et al. investigated the use of ML and cognitive tests to identify first-episode BD patients (13). The study included 121 participants (40 first-episode BD, 41 first-episode MDD, and 40 healthy controls) who underwent cognitive tests. The authors applied various ML algorithms, such as SVM, RF, and ANN, to identify first-episode BD based on cognitive performance. The best-performing model (ANN) achieved an accuracy of 92.5% in identifying first-episode BD, highlighting the potential of ML and mental tests in the early detection of BD.

2456

DISCUSSION

The findings of this narrative review underscore AI's potential to revolutionize BD management by enhancing diagnostic accuracy, enabling continuous monitoring, and predicting clinical outcomes. AI techniques, such as ML and ANN, have shown promising results in differentiating BD from other psychiatric conditions, with accuracies ranging from 49.5% to 96.2% (4–6). These advancements can aid clinicians in making accurate and timely diagnoses, facilitating early intervention and appropriate treatment.

Moreover, AI-powered monitoring systems utilizing smartphones and wearable devices have demonstrated the ability to detect prodromal symptoms and predict mood episode recurrences with high accuracy (9,10). Monitoring mood fluctuations can provide valuable

insights into an individual's condition, enabling personalized treatment approaches and early intervention to prevent relapses.

AI-driven predictive models have also shown potential in identifying cognitive dysfunctions in the early stages of BD and predicting depressive relapses (12,13). By leveraging these predictive capabilities, clinicians can develop targeted interventions and optimize treatment strategies to improve patient outcomes and prevent relapses.

However, the effective implementation of AI in BD management faces several challenges, including data heterogeneity, the need for external validation, and ethical considerations (2,14). Addressing these challenges requires collaborative efforts from researchers, clinicians, and policymakers to develop standardized datasets, validate AI models across diverse populations, and establish ethical guidelines for the responsible use of AI in mental healthcare.

CONCLUSION

AI can transform BD's management by enhancing diagnostic accuracy, enabling continuous monitoring, and predicting clinical outcomes. The current research demonstrates promising applications of AI techniques, such as ML and ANN, in differentiating BD from other psychiatric conditions, monitoring mood fluctuations, and predicting relapses. However, further research and methodological improvements are necessary to address challenges related to data heterogeneity, external validation, and ethical considerations. As AI continues to advance, it is crucial to foster interdisciplinary collaborations and engage stakeholders, including patients, clinicians, researchers, and policymakers, to ensure AI's responsible and effective integration into the management of BD.

2457

Future research should focus on developing large-scale, diverse datasets that capture the heterogeneity of BD and enable the development of robust and generalizable AI models. Additionally, external validation of AI models across different populations and settings is essential to ensure their clinical utility and reliability. Researchers should also prioritize the interpretability and explainability of AI models to facilitate their adoption and trust among clinicians and patients.

Moreover, addressing ethical considerations, such as data privacy, informed consent, and potential biases, is crucial for the responsible implementation of AI in BD management. Establishing ethical guidelines and involving patients in developing and deploying AI-driven systems can help ensure these technologies align with patient needs and values.

In conclusion, AI holds immense promise in revolutionizing the management of BD by improving diagnostic accuracy, enabling continuous monitoring, and predicting clinical outcomes. However, realizing this potential requires a concerted effort from all stakeholders to address data quality, validation, and ethics challenges. By harnessing the power of AI responsibly and collaboratively, we can pave the way for more personalized, effective, and accessible care for individuals with BD, ultimately improving their quality of life and long-term outcomes.

REFERENCES

1. MALHI GS. Bipolar disorders: key clinical considerations. Lancet [Internet]. 2016 Apr 9 [cited 2024 Jun 2];387(10027):1492–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27115960

2. DAKANALIS A, Wiederhold BK, Riva G. Artificial Intelligence: A Game-Changer for Mental Health Care. Cyberpsychol Behav Soc Netw [Internet]. 2024 Feb;27(2):100–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38358832

3. BOBO W V. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc [Internet]. 2017 Oct;92(10):1532–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28888714

4. EDAVALLY S, Miller DD, Youssef NA. Artificial intelligence to aid detection and diagnostic accuracy of mood disorders and predict suicide risk: A systematic review. Ann Clin Psychiatry [Internet]. 2021 Nov;33(4):270–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34672929

5. CLAUDE LA, Houenou J, Duchesnay E, Favre P. Will machine learning applied to neuroimaging in bipolar disorder help the clinician? A critical review and methodological suggestions. Bipolar Disord [Internet]. 2020 Jun;22(4):334–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32108409

6. JAN Z, Ai-Ansari N, Mousa O, Abd-Alrazaq A, Ahmed A, Alam T, et al. The Role of Machine Learning in Diagnosing Bipolar Disorder: Scoping Review. J Med Internet Res

2458

Revista Ibero-Americana de Humanidades, Ciências e Educação. São Paulo, v. 10, n. 08, ago. 2024.

ISSN: 2675-3375

[Internet]. 2021 Nov 19;23(11):e29749. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34806996

7. KOUTSOULERIS N, Meisenzahl EM, Borgwardt S, Riecher-Rössler A, Frodl T, Kambeitz J, et al. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain [Internet]. 2015 Jul;138(Pt 7):2059–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25935725

8. FAURHOLT-Jepsen M, Frost M, Christensen EM, Bardram JE, Vinberg M, Kessing LV. The effect of smartphone-based monitoring on illness activity in bipolar disorder: the MONARCA II randomized controlled single-blinded trial. Psychol Med [Internet]. 2020 Apr;50(5):838–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30944054

9. ANTOSIK-Wójcińska AZ, Dominiak M, Chojnacka M, Kaczmarek-Majer K, Opara KR, Radziszewska W, et al. Smartphone as a monitoring tool for bipolar disorder: a systematic review including data analysis, machine learning algorithms, and predictive modeling. Int J Med Inform [Internet]. 2020 Jun;138:104131. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32305023

10. VALENZA G, Gentili C, Lanatà A, Scilingo EP. Mood recognition in bipolar patients through the PSYCHE platform: preliminary evaluations and perspectives. Artif Intell Med [Internet]. 2013 Jan;57(1):49–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23332576

11. FAURHOLT-Jepsen M, Busk J, Frost M, Vinberg M, Christensen EM, Winther O, et al. Voice analysis as an objective state marker in bipolar disorder. Transl Psychiatry [Internet]. 2016 Jul 19;6(7):e856. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27434490

12. ROTENBERG L de S, Borges-Júnior RG, Lafer B, Salvini R, Dias R da S. Exploring machine learning to predict depressive relapses of bipolar disorder patients. J Affect Disord [Internet]. 2021 Dec 1;295:681–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34509784

13. SAWALHA J, Cao L, Chen J, Selvitella A, Liu Y, Yang C, et al. Individualized identification of first-episode bipolar disorder using machine learning and cognitive tests. J Affect Disord [Internet]. 2021 Mar 1;282:662–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33445089

14. PASSOS IC, Ballester PL, Barros RC, Librenza-Garcia D, Mwangi B, Birmaher B, et al. Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. Bipolar Disord [Internet]. 2019 Nov;21(7):582–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31465619

Revista Ibero-Americana de Humanidades, Ciências e Educação. São Paulo, v. 10, n. 08, ago. 2024.

ISSN: 2675-3375